New evidence of RSV long-acting antibody protection

Sanofi today announced that an analysis of data from the latest clinical trial of nirsevimab, a long-acting antibody therapy for respiratory syncytial virus (RSV), shows that in children entering their first RSV season, nirsevimab will reduce the need for treatment due to RSV infecti.

RSV is a common infectious agent that causes seasonal epidemics of LRTI, including bronchitis and pneumonia, and is the leading cause of hospitalization in infants worldwi.

This pre-specified meta-analysis pooled data from the pivotal Phase 3 clinical trial MELODY and the Phase 2b clinical tri.

Another post hoc analysis found that nirsevimab-treated infants had blood levels of RSV-neutralizing antibodies 50 times higher than baseline levels after 151 da.

"RSV remains the most common cause of LRTI in infants, causing seasonal epidemics each ye.

References:

[1] Press Release: New nirsevimab data analyses reinforce efficacy against R.